Researchers developed a pipeline to identify tumor-specific peptide antigens in metastatic breast cancer and created a vaccine that prevented tumor development in mice by generating cancer-killing T cell responses.
Vaccination prevented tumor developmentA DNA vaccine targeting five identified tumor-specific peptide epitopes generated CD8+ killer T cell responses and completely prevented tumor development in a mouse model of metastatic breast cancer.
What the researchers found
The research team deployed their NetH2pan prediction tool combined with advanced proteomics to identify five unique MHC class I/PyMT peptide epitopes in the MMTV-PyMT transgenic breast cancer model. These tumor-specific peptides were confirmed to be naturally presented on the surface of primary tumors by MHC class I molecules.
T cell immunogenicity of all five epitopes was validated — meaning the immune system could recognize and respond to these peptides. A DNA vaccine encoding a truncated PyMT protein generated CD8+ T cell responses targeting these specific MHC class I/peptide complexes and prevented tumor development in the metastatic breast cancer model.
Why it matters
Breast cancer remains a leading cause of cancer death, and metastatic breast cancer has been particularly resistant to immunotherapy compared to cancers like melanoma. A major barrier has been identifying which peptide targets the immune system should attack. This study establishes a complete pipeline — from prediction to validation to vaccination — that could be adapted for human breast cancer and other tumor types, potentially enabling personalized cancer vaccines.
How the study worked
The researchers first built an MHC ligand prediction tool (NetH2pan) for the FVB/NJ mouse strain by creating an H-2q ligand database combined with data from six other murine MHC alleles. They then used this tool alongside advanced proteomics (mass spectrometry) to identify peptides presented on tumor cell surfaces. Candidate peptides were validated for T cell immunogenicity. A DNA construct encoding truncated PyMT protein was used as a vaccine, and tumor prevention was assessed in MMTV-PyMT transgenic mice.
What this study cannot tell us
All experiments were conducted in mice using a transgenic breast cancer model. The MMTV-PyMT model, while well-established for studying breast cancer biology, uses a viral oncogene (PyMT) that doesn't exist in human breast cancer — so the specific peptide targets identified here are not directly applicable to human patients. The vaccine was tested preventively (before tumor development), and whether it would work against established tumors is unknown. Translation to human breast cancer would require identifying human-relevant neoantigens using the same pipeline approach.
How to read the evidence
This is a preclinical study using a transgenic mouse model of breast cancer. The pipeline validation and proof-of-concept vaccination are scientifically rigorous, but the findings are limited to a single mouse model with a viral oncogene not present in human breast cancer.
When this study was published
Published in 2020, this study is about 6 years old. The neoantigen discovery pipeline approach it demonstrates has influenced subsequent work in personalized cancer vaccine development, and the field has advanced rapidly since then.
The bigger picture
Cancer vaccines based on tumor-specific peptides are one of the most exciting frontiers in oncology. While mRNA cancer vaccines (similar to COVID vaccines) have grabbed headlines, peptide-based approaches remain important for their specificity and potential for off-the-shelf products. This study addresses a critical gap — the lack of validated tumor antigens for breast cancer immunotherapy — and provides a reusable discovery pipeline that could accelerate antigen identification across cancer types.
Questions still open
- Can this antigen discovery pipeline be successfully applied to identify human breast cancer neoantigens for clinical vaccine development?
- Would this vaccine approach be effective against established metastatic tumors, not just as a preventive strategy?
- Could this pipeline be combined with immune checkpoint inhibitors for synergistic anti-tumor effects?
Common questions
How does a cancer peptide vaccine work?
Could this approach lead to a breast cancer vaccine for humans?
Read the original research
A pipeline for identification and validation of tumor-specific antigens in a mouse model of metastatic breast cancer.
Oncoimmunology, 9(1), 1685300
Citation
DeVette, Christa I; Gundlapalli, Harika; Lai, Shu-Chin Alicia; McMurtrey, Curtis P; Hoover, Ashley R; Gurung, Hem R; Chen, Wei R; Welm, Alana L; Hildebrand, William H. (2020). A pipeline for identification and validation of tumor-specific antigens in a mouse model of metastatic breast cancer.. Oncoimmunology, 9(1), 1685300. https://doi.org/10.1080/2162402X.2019.1685300